National Healthcare Security Administration recently conducted a preliminary formal review of the drug declaration data for the adjustment of the medical insurance drug catalogue in 2022, and published the list of drugs and related information that passed the preliminary formal examination. The list shows that the first domestic COVID-19 oral drug azvudine tablets has passed the preliminary formal examination of the adjustment of the national health insurance drug catalogue.
国家医保局：首个国产新冠口服药通过医保目录调整初步审查
National Healthcare Security Administration: the first domestic COVID-19 oral drug passed the preliminary examination of the adjustment of the medical insurance catalogue.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.